Biogen (BIIB) Stock May Be 45% Undervalued Despite Fresh Kidney Data

Biogen has delivered a strong run over the past year, and the key issue for you now is whether the current share price lines up with the cash the business is expected to generate. After a move like this, the question is how much of Biogen’s future cash flows the market may already be pricing in. Biogen has returned 67.7% over the past year, which puts real pressure on the question of whether recent gains are fully supported by its underlying cash flow potential. Fresh data around EMPAVELI...